Last reviewed · How we verify
Cohort 1 CTAP101 Capsules- 60µg — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Cohort 1 CTAP101 Capsules- 60µg (Cohort 1 CTAP101 Capsules- 60µg) — OPKO Health, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cohort 1 CTAP101 Capsules- 60µg TARGET | Cohort 1 CTAP101 Capsules- 60µg | OPKO Health, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cohort 1 CTAP101 Capsules- 60µg CI watch — RSS
- Cohort 1 CTAP101 Capsules- 60µg CI watch — Atom
- Cohort 1 CTAP101 Capsules- 60µg CI watch — JSON
- Cohort 1 CTAP101 Capsules- 60µg alone — RSS
Cite this brief
Drug Landscape (2026). Cohort 1 CTAP101 Capsules- 60µg — Competitive Intelligence Brief. https://druglandscape.com/ci/cohort-1-ctap101-capsules-60-g. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab